The latest research you need to know

The Hospitalist. 2009 April;2009(04):

April 1, 2009 | The Hospitalist

Michael Kedansky, MD ; Victor Weaver, MD ; Michael Goldman, MD ; Lisa Gushwa, MD ; Paul Hicks, MD ; Barbara Eckstein, MD ; Christine Kneisel, MD ; Department Of Family ; Community Medicine ; University Of Arizona

Bottom line: Low-dose aspirin used in patients with Type 2 diabetes does not significantly demonstrate primary prevention of cardiovascular events.

Citation: Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300(18):2134-2141. TH